<blockquote>It essentially rations the country's medicine bill and saves tax-payer money by being able to negotiate bulk deals, often for generic drugs just as a leading and more expensive drug is coming out of its patent period.

But Pharmac is seen by the United States' pharmaceutical industry as anti-competitive, lacking transparency in its decisions, limiting the range of drugs on offer to New Zealanders and not giving intellectual property and research their due rewards.</blockquote>
via <a href="http://www.nzherald.co.nz/business/news/article.cfm?c_id=3&amp;objectid=11463685">TPP won't lead to higher prescription prices - PM - Business - NZ Herald News</a>.
<blockquote>Anti-TPP campaigner and Auckland University law professor Jane Kelsey told reporters today that the US pharmaceutical industry had Pharmac in its sights because it was seen as a highly successful model (for New Zealand) and did not want it replicated elsewhere in countries such as Vietnam.</blockquote>